Reviva Pharmaceuticals Holdings, Inc. Files 8-K
Ticker: RVPH · Form: 8-K · Filed: May 15, 2024
Sentiment: neutral
Topics: corporate-filing, company-information
TL;DR
REVIVA PHARMACEUTICALS HOLDINGS, INC. FILED AN 8-K ON 5/15/24. NOTHING MAJOR REPORTED YET.
AI Summary
Reviva Pharmaceuticals Holdings, Inc. filed an 8-K on May 15, 2024, reporting on various events. The filing includes information about the company's structure, incorporation in Delaware, and business address in Cupertino, CA. It also lists the company's former name as Tenzing Acquisition Corp., with a name change date of June 6, 2018.
Why It Matters
This 8-K filing provides official updates and disclosures from Reviva Pharmaceuticals Holdings, Inc. to the SEC, which are important for investors to stay informed about the company's status and any material events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not appear to contain any immediately concerning or high-risk information.
Key Players & Entities
- REVIVA PHARMACEUTICALS HOLDINGS, INC. (company) — Registrant
- Tenzing Acquisition Corp. (company) — Former company name
- May 15, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 10080 N Wolfe Road, Suite SW3-200 (address) — Business address
- Cupertino, CA (location) — Business address city and state
FAQ
What is the primary purpose of this 8-K filing for Reviva Pharmaceuticals Holdings, Inc.?
This 8-K filing serves as a Current Report for Reviva Pharmaceuticals Holdings, Inc., reporting on events that may be of importance to shareholders and the SEC, including Regulation FD Disclosures, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on May 15, 2024.
What was Reviva Pharmaceuticals Holdings, Inc. formerly known as?
Reviva Pharmaceuticals Holdings, Inc. was formerly known as Tenzing Acquisition Corp.
On what date did the company change its name from Tenzing Acquisition Corp.?
The company changed its name from Tenzing Acquisition Corp. on June 6, 2018.
In which state is Reviva Pharmaceuticals Holdings, Inc. incorporated?
Reviva Pharmaceuticals Holdings, Inc. is incorporated in Delaware.
Filing Stats: 690 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2024-05-15 08:10:18
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share RVPH Nasdaq Capital Marke
Filing Documents
- rvph20240514_8k.htm (8-K) — 34KB
- ex_674720.htm (EX-99.1) — 19KB
- 0001437749-24-016796.txt ( ) — 205KB
- rvph-20240515.xsd (EX-101.SCH) — 4KB
- rvph-20240515_def.xml (EX-101.DEF) — 13KB
- rvph-20240515_lab.xml (EX-101.LAB) — 17KB
- rvph-20240515_pre.xml (EX-101.PRE) — 13KB
- rvph20240514_8k_htm.xml (XML) — 5KB
01
Item 7.01. Regulation FD Disclosure. On May 15, 2024, Reviva Pharmaceuticals Holdings, Inc. (the "Company") issued a press release announcing an enrollment update to the RECOVER ongoing 1-year open label extension ("OLE") study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
01
Item 8.01. Other Events. On May 15, 2024, the Company announced the following enrollment status update for the RECOVER trial: Trial progressing as expected in the USA, Europe (Bulgaria) and Asia (India) 358 patients enrolled in the study 223 patients currently on treatment in the study Over 130 patients currently in the study have completed 1-6 months of treatment Over 90 patients currently in the study have completed 6-9 months of treatment 23 patients have completed 12 months of treatment Long-term safety data from 100 patients who have completed 12 months of treatment is a requirement for brilaroxazine's NDA submission to the FDA Reviva is on track to complete the 12 months long-term safety study in Q4 2024
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) The following exhibit is furnished with this report: Exhibit No. Description 99.1 Press Release issued by Reviva Pharmaceuticals Holdings, Inc., dated May 15, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REVIVA PHARMACEUTICALS HOLDINGS, INC. Dated: May 15, 2024 By: /s/ Narayan Prabhu Name: Title: Narayan Prabhu Chief Financial Officer